On 15 MAY Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) announced discontinuation of the planned Phase 3 clinical trial for Impracor. During our 2013 fiscal year, Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) began re-focusing business plan away from the development of Impracor and toward our current formulation and technology development and compounding pharmacy business model. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) weekly performance is -8.55%. On last trading day company shares ended up $5.67. Analysts mean target price for the company is $2.00. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) distance from 50-day simple moving average (SMA50) is -18.97%.
Dendreon Corporation (NASDAQ:DNDN) has commenced sale of Provenge, its vaccine that can prevent prostrate cancer. This news has brought a lot of hope in the market. Dendreon Corporation (NASDAQ:DNDN) shares advanced 7.94% in last trading session and ended the day on $2.31. DNDN Gross Margin is 41.40% and its return on assets is -54.60%. Dendreon Corporation (NASDAQ:DNDN) quarterly performance is -22.74%.
Ophthotech Corp (NASDAQ:OPHT) announced that the Company has entered into an ex-US licensing and commercialization agreement with Novartis Pharmaceuticals (NYSE: NVS) focused on the treatment of wet age-related macular degeneration (AMD).Ophthotech Corp (NASDAQ:OPHT) shares moved up 24.48% in last trading session and was closed at $39.16, while trading in range of $36.75 – $40.88. Ophthotech Corp (NASDAQ:OPHT) year to date (YTD) performance is 21.05%.
Insmed Incorporated (NASDAQ:INSM) announced additional results from the Company’s phase 2 clinical trial of ARIKAYCETM, or liposomal amikacin for inhalation, for the treatment of patients with treatment resistant nontuberculous mycobacterial (NTM) lung infections. Insmed Incorporated (NASDAQ:INSM) ended the last trading day at $13.97. Company weekly volatility is calculated as 11.28% and price to cash ratio as 5.42. Insmed Incorporated (NASDAQ:INSM) showed a negative weekly performance of -8.45%.
Neuralstem, Inc. (NYSEMKT:CUR) CEO and President, Richard Garr, will present at the World Stem Cells & Regenerative Medicine Congress, on Thursday, May 22, at 11:35 a.m. BST in London, UK. Neuralstem, Inc. (NYSEMKT: CUR) is currently in a Phase II clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig’s disease) with its NSI-566 stem cells and has been approved to commence a Phase I study in spinal cord injury with the same cells. The company has also completed a Phase Ib trial testing its first-in-class neurogenic compound, NSI-189; in patients with major depressive disorder (MDD). Neuralstem, Inc. (NYSEMKT:CUR) weekly performance is 18.10%. On last trading day company shares ended up $3.72. Analysts mean target price for the company is $4.50. Neuralstem, Inc. (NYSEMKT: CUR) distance from 50-day simple moving average (SMA50) is -3.32%.